PTCT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PT

Mkt Cap

$4.94B

Volume

559.45K

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields SurgeThe Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.The Motley Fool · Oct 5, 2026

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 MillionPTC Therapeutics' chief technical operations officer sold 2,464 shares under a routine pre-established trading plan, generating $222,376. The insider retains substantial holdings of 63,198 shares plus 45,036 derivative securities. The sale is routine equity compensation management and not indicative of concern, as the company demonstrates strong commercial momentum with Q1 product revenue of $225.6 million, driven by PKU drug Sephience's $124.6 million in sales (up 36% quarterly). Management raised full-year product revenue guidance to $750-850 million.The Motley Fool · Jul 13, 2026

What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.Benzinga · Dec 31, 2025

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential MilestonesRoyalty Pharma has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in sales-based milestones. Following the transaction, Royalty Pharma will own 100% of the tiered 8% to 16% royalty on worldwide net sales of Evrysdi, an FDA-approved spinal muscular atrophy treatment that generated approximately $1.9 billion in sales in 2024 with projected growth to $2.9 billion by 2030.Benzinga · Dec 29, 2025

Here's Why Shares in PTC Therapeutics Soared This WeekPTC Therapeutics' CEO Matthew Klein highlighted the commercial potential of Sephience, a drug for treating phenylketonuria (PKU), projecting significant market opportunities in the U.S. and internationally. The company expects to reach cash flow breakeven with growing sales and believes most patients will respond positively to the treatment.The Motley Fool · Sep 5, 2025

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidanceNovartis reported strong Q2 2025 financial performance with 11% sales growth, double-digit core operating income increase, and raised full-year guidance. Key growth drivers included oncology and specialty medicine brands like Kisqali, Entresto, and Pluvicto.GlobeNewswire Inc. · Jul 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRPomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.GlobeNewswire Inc. · Jun 2, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTPomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTCT) due to concerns about the company's securities fraud or other unlawful business practices. The investigation is related to the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Huntington's disease patients.GlobeNewswire Inc. · Jun 2, 2025

RNA Targeting Small Molecule Drug Discovery Research Report 2025 - Global $5.52 Bn Market Trends, Opportunities, and Forecasts, 2020-2030FThe RNA Targeting Small Molecule Drug Discovery Market is expected to grow significantly, driven by advancements in RNA biology and AI-driven drug discovery. However, the complexity of RNA structures and target specificity pose challenges for the industry.GlobeNewswire Inc. · May 29, 2025

Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsightThe mitochondrial disease market is witnessing steady growth, driven by increasing awareness, improved genetic diagnostics, and advancements in personalized medicine. The article provides insights into the market landscape for Leigh Syndrome, Leber's Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency.GlobeNewswire Inc. · May 26, 2025

PT

PTCTPTC Therapeutics, Inc.

PTCT

Pay with—

Available Balance0.00

Your PositionYou don't own any PTCT yet.

Related Tickers

Earnings